arrow
N

Normand Blais

université de montreal
H指数:53
被引数:9,941

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Pragmatic Management of EGFR-Mutant NSCLC After Progression on Osimertinib: Canadian Expert Perspectives

奥希替尼进展后EGFR突变非小细胞肺癌的实用管理:加拿大专家观点

2026-09-070
OA
A population-based analysis of patterns of care in patients with de novo muscle-invasive bladder cancer from Alberta, Canada

一项基于人群的分析,研究加拿大艾伯塔省新发肌层浸润性膀胱癌患者的治疗模式。

2025-12-010
PRE
Neoadjuvant chemo-immunotherapy in Non-Small Cell Lung Cancer: Can Positron Emission Tomography scan predict complete pathological response?

非小细胞肺癌的新辅助化疗免疫治疗:正电子发射断层扫描能否预测完全病理缓解?

2025-10-280
PRE
A population-based analysis of patterns of care in patients with high-risk non-muscle-invasive bladder cancer from Alberta, Canada

来自加拿大阿尔伯塔省的高风险非肌层浸润性膀胱癌患者护理模式的人口基础分析

2025-10-011
OAAI
Guiding first-line treatment decisions in advanced urothelial carcinoma: a global survey

指导晚期尿路上皮癌一线治疗决策:一项全球调查

2025-10-010
OAAI
Intracranial activity of sotorasib vs docetaxel in pretreated KRAS G12C-mutated advanced non-small cell lung cancer from a global, phase 3, randomized controlled trial

索托拉西布与多西他赛在经治KRAS G12C突变型晚期非小细胞肺癌中的颅内活性比较:一项全球性、III期、随机对照试验

2025-07-290
OAAI
Avelumab plus sacituzumab govitecan versus avelumab monotherapy as first-line maintenance treatment in patients with advanced urothelial carcinoma: JAVELIN Bladder Medley interim analysis☆

阿维鲁姆单抗联合沙西妥珠单抗戈维他胺与阿维鲁姆单抗单药治疗作为晚期尿路上皮癌患者的一线维持治疗方案:JAVELIN Bladder Medley研究中期分析☆

2025-06-010
OAAI
Sotorasib versus docetaxel for previously treated KRAS G12C-mutated non-small-cell lung cancer: a plain language summary
2025-03-010
OAAI
Management of bleeding and invasive procedures in patients treated with anti–factor XI(a) anticoagulants: proposals from the French Working Group on Perioperative Haemostasis and French Society of Thrombosis and Haemostasis

抗凝血因子XI(a)患者在出血和侵入性操作中的管理:法国围手术期止血工作组及法国血栓与止血学会的建议

2025-03-010
OAAI
CRYOVATE: A Pilot Study of Lung Cancer Cryoactivation in Combination With Immunotherapy in Advanced NSCLC
2024-12-011
OA
Prevention of perioperative venous thromboembolism: 2024 guidelines from the French Working Group on Perioperative Haemostasis (GIHP) developed in collaboration with the French Society of Anaesthesia and Intensive Care Medicine (SFAR), the French Society of Thrombosis and Haemostasis (SFTH) and the French Society of Vascular Medicine (SFMV) and endorsed by the French Society of Digestive Surgery (SFCD), the French Society of Pharmacology and Therapeutics (SFPT) and INNOVTE (Investigation Network On Venous ThromboEmbolism) network

围术期静脉血栓栓塞症的预防:法国围术期止血工作组(GIHP)2024年指南,由其与法国麻醉与重症医学学会(SFAR)、法国血栓与止血学会(SFTH)和法国血管医学学会(SFMV)合作制定,并得到法国消化外科学会(SFCD)、法国药理学与治疗学学会(SFPT)以及INNOVTE(静脉血栓栓塞症研究网络)的支持。

2024-10-220
OAAI
Sotorasib versus docetaxel for previously treated non-small- cell lung cancer with KRASG12C mutation: a randomised, open-label, phase 3 trial

Sotorasib与多西他赛治疗KRASG12C突变的非小细胞肺癌: 一项随机,开放标签,3期试验

LANCET
IF88.5
2023-03-01219
OAAI